The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigatorswith peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-openedsouth campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops andprovides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assayshave been established and modified for multiparametric analysis. Immunophenotypic analysis was combinedwith assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation,mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA,DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybindingcapacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolatedby three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysisby molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax,Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays todiscriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimalresidual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods fordetection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factorreceptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and afour-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation andanalysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of anOlympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies incancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multisteptumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. TheCore supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number ofusers has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% ofusers have peer-reviewed funding. During the previous funding period, 11,668 hours of service wasprovided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on thecontinued development and application of cutting-edge technologies in cell analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-33
Application #
7695941
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-28
Project End
2013-06-30
Budget Start
2008-08-28
Budget End
2009-06-30
Support Year
33
Fiscal Year
2008
Total Cost
$359,564
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Qian, Xu; Li, Xinjian; Tan, Lin et al. (2018) Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress. Cancer Discov 8:94-107
Dashti, S Ghazaleh; Win, Aung Ko; Hardikar, Sheetal S et al. (2018) Physical activity and the risk of colorectal cancer in Lynch syndrome. Int J Cancer 143:2250-2260
Livingston, J Andrew; Wang, Wei-Lien; Tsai, Jen-Wei et al. (2018) Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther 17:1315-1323
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Vijayaraghavan, Smruthi; Moulder, Stacy; Keyomarsi, Khandan et al. (2018) Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol 13:21-38
Tsai, Edward; Robertson, Michael C; Lyons, Elizabeth J et al. (2018) Physical activity and exercise self-regulation in cancer survivors: A qualitative study. Psychooncology 27:563-568
Rosenstock, Aron S; Niu, Jiangong; Giordano, Sharon H et al. (2018) Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer 124:899-906
Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua et al. (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173:321-337.e10
Fleming, Nicole D; Nick, Alpa M; Coleman, Robert L et al. (2018) Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132:545-554

Showing the most recent 10 out of 12418 publications